Qube Research & Technologies (QRT)’s Entrada Therapeutics TRDA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$448K	Sell	60,872 -26,581	-30%	-$255K	﹤0.01%	2685
2026 Q1	$1.1M	Sell	87,453 -88,565	-50%	-$1.01M	﹤0.01%	2444
2025 Q4	$1.81M	Sell	176,018 -111,855	-39%	-$943K	﹤0.01%	2308
2025 Q3	$1.67M	Buy	287,873 +154,143	+115%	+$902K	﹤0.01%	2317
2025 Q2	$899K	Buy	133,730 +108,737	+435%	+$875K	﹤0.01%	2503
2025 Q1	$226K	Buy	+24,993	New	+$311K	﹤0.01%	2833
2023 Q2	–	Sell	-38,782	Closed	-$562K	–	3021
2023 Q1	$562K	Buy	38,782 +22,000	+131%	+$294K	﹤0.01%	1525
2022 Q4	$227K	Buy	+16,782	New	+$294K	﹤0.01%	1761

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TRDA Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Entrada Therapeutics (TRDA) stake by 30% in Q2 2026, selling an estimated $255K and leaving 60,872 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

Qube Research & Technologies (QRT) first reported a position in TRDA in Q4 2022 and has held it in 8 quarters since. The position peaked at $1.81M in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Qube Research & Technologies (QRT) held 60,872 shares of Entrada Therapeutics worth $448K as of Q2 2026.
Qube Research & Technologies (QRT) sold 26,581 Entrada Therapeutics shares in Q2 2026, an estimated $255K.
Entrada Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2685 holding.
Qube Research & Technologies (QRT) first reported a position in Entrada Therapeutics in Q4 2022 and has held it in 8 quarters since.
Qube Research & Technologies (QRT)'s Entrada Therapeutics position peaked at $1.81M in Q4 2025.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.